Boston University-Based Biopharmaceutical Accelerator Boosts New Drugs’ Chances of Success, Study Finds
CARB-X-backed novel therapeutics to combat antimicrobial resistance are nearly five times more likely to reach clinical development.
WHO Joins Forces with BU Center on Forced Displacement to Help Vulnerable Populations at Risk of Antimicrobial Resistance
Collaboration will study link between environmental pollution and drug-resistant infections among refugees and asylum seekers.
WHO Reports 40 Percent Jump in Antibiotic-Resistant infections; BU-Based Nonprofit Leads the Fight Back
CARB-X, an antibiotics research accelerator, is helping bring new medicines, vaccines, and tests to clinics worldwide.